Exploring the cause of drug resistance by the detrimental missense mutations in KIT receptor: Computational approach

Amino Acids

Volumn 39, Issue 3, 2010, Pages 651-660

  Rajasekaran, R ^a   Sethumadhavan, Rao ^a  

^a VIT UNIVERSITY   (India)

Author keywords

Flexibility; Imatinib; KIT receptor; Missense mutation

Indexed keywords

ALANINE; AMINO ACID; ARGININE; ASPARAGINE; ASPARTIC ACID; CYSTINE; GLUTAMIC ACID; IMATINIB; ISOLEUCINE; KIT RECEPTOR PROTEIN; LEUCINE; LYSINE; MUTANT PROTEIN; PHENYLALANINE; PROLINE; THREONINE; TRYPTOPHAN; TYROSINE; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VALINE; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN BINDING; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG RESISTANCE; GASTROINTESTINAL STROMAL TUMOR; MATHEMATICAL COMPUTING; MISSENSE MUTATION; MOLECULAR DOCKING; POLYPHEN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STABILITY; PROTEIN VARIANT; SEQUENCE DATABASE; SIFT; SUPPORT VECTOR MACHINE; BINDING SITE; BIOLOGY; CHEMISTRY; CONFORMATION; GASTROINTESTINAL STROMAL TUMORS; GENETICS; HUMAN; METABOLISM;

BINDING SITES; COMPUTATIONAL BIOLOGY; DRUG RESISTANCE, NEOPLASM; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MOLECULAR CONFORMATION; MUTATION, MISSENSE; PIPERAZINES; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; BENZAMIDES;

EID: 77956935919     PISSN: 09394451     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00726-010-0486-6     Document Type: Article

References (61)

1. Bauer S, Hartmann JT, de WM, Lang H, Grabellus F, Antoch G, Niebel W, Erhard J, Ebeling P, Zeth M (2005) Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer 117:316-325
2. Bauer S, Yu LK, Demetri GD, Fletcher JA (2006) Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 66(18):9153-9161
3. Bava KA, Gromiha MM, Uedaira H, Kitajima K, Sarai A (2004) ProTherm, version 4.0: thermodynamic database for proteins and mutants. Nucleic Acids Res 32:120-121
4. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) The Protein Data Bank. Nucleic Acids Res 28(1):235-242
5. Blechman JM, Lev S, Barg J, Eisenstein M, Vaks B, Vogel Z, Givol D, Yarden Y (1995) The fourth immunoglobulin domain of the stem cell factor receptor couples ligand binding to signal transduction. Cell 80:103-113
6. Blume-Jensen P, Hunter T (2001) Oncogenic kinase signaling. Nature 411:355-365
7. Boeckmann B, Bairoch A, Apweiler R, Blatter MC, Estreicher A, Gasteiger E, Martin MJ, Michoud K, O'Donovan C, Phan I, Pilbout S, Schneider M (2003) The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003. Nucleic Acids Res 31(1):365-370
8. Capriotti E, Fariselli P, Casadio R (2005) I-Mutant2.0: predicting stability changes upon mutation from the protein sequence or structure. Nucleic Acids Res 33:306-310
9. Carlson HA, McCammon JA (2000) Accommodating protein flexibility in computational drug design. Mol Pharmacol 57:213-218
10. Cavallo A, Martin AC (2005) Mapping SNPs to protein sequence and structure data. Bioinformatics 21(8):1443-1450
11. Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, Raymond AK, Prieto VG, Oyedeji CO, Hunt KK, Pollock RE, Feig BW, Hayes KJ, Choi H, Macapinlac HA, Hittelman W, Velasco MA, Patel S, Burgess MA, Benjamin RS, Frazier ML (2004) A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 64(17):5913-5919
12. Chen LL, Sabripour M, Andtbacka RH, Patel SR, Feig BW, Macapinlac HA, Choi H, Wu EF, Frazier ML, Benjamin RS (2005) Imatinib resistance in gastrointestinal stromal tumors. Curr Oncol Rep 7(4):293-299
13. Ciccarelli FD, Acciarito A, Alberti S (2000) Large and diverse numbers of human diseases with HIKE mutations. Hum Mol Genet 9(6):1001-1007
14. Connolly ML (1983a) Solvent-accessible surfaces of proteins and nucleic acids. Science 221(4612):709-713
15. Connolly ML (1983b) Analytical molecular surface calculation. J Appl Cryst 16:548-558
16. Debiec-Rychter M, Cools J, Dumez H, Sciot R, Stul M, Mentens N, Vranckx H, Wasag B, Prenen H, Roesel J, Hagemeijer A, Van Oosterom A, Marynen P (2005) Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 128(2):270-279
17. Delarue M, Dumas P (2004) On the use of low-frequency normal modes to enforce collective movements in refining macromolecular structural models. Proc Natl Acad Sci USA 101(18): 6957-6962
18. Duhovny D, Nussinov R, Wolfson HJ (2002) Efficient unbound docking of rigid molecules. In: Gusfield D et al (eds) Proceedings of the second workshop on algorithms in bioinformatics (WABI) Lecture Notes in Computer Science, vol 2452, Springer, Rome, Italy, pp 185-200
19. Engelman JA, Settleman J (2008) Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev 18:73-79
20. Fletcher JA, Rubin BP (2007) KIT mutations in GIST. Curr Opin Genet Dev 17(1):3-7
21. Gajiwala KS, Wu JC, Christensen J, Deshmukh GD, Diehl W, Dinitto JP, English JM, Greig MJ, He YA, Jacques SL, Lunney EA, McTigue M, Molina D, Quenzer T, Wells PA, Yu X, Zhang Y, Zou A, Emmett MR, Marshall AG, Zhang HM, Demetri GD (2009) KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci USA 106(5):1542-1547
22. Growney JD, Clark JJ, Adelsperger J, Stone R, Fabbro D, Griffin JD, Gilliland DG (2005) Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood 106(2):721-724
23. Guo T, Agaram NP, Wong GC, Hom G, D'Adamo D, Maki RG, Schwartz GK, Veach D, Clarkson BD, Singer S, DeMatteo RP, Besmer P, Antonescu CR (2007) Sorafenib inhibits the imatinibresistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res 13(16):4874-4881
24. Gupta P, Tewari M, Shukla HS (2008) Gastrointestinal stromal tumor. Surg Oncol 17(2):129-138
25. Han JH, Kerrison N, Chothia C, Teichmann SA (2006) Divergence of interdomain geometry in two-domain proteins. Structure 14(5):935-945
26. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M, Fletcher CD, Sandau K, McDougall K, Ou WB, Chen CJ, Fletcher JA (2006) Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24(29):4764-4774
27. Hinkle A, Tobacman LS (2003) Folding and function of the troponin tail domain. Effects of cardiomyopathic troponin T mutations. J Biol Chem 278(1):506-513
28. Jonathan Fletcher A, Brian Rubin P (2007) KIT mutations in GIST. Curr Opin Genet Dev 17:3-7
29. Kemmer K, Corless CL, Fletcher JA, McGreevey L, Haley A, Griffith D, Cummings OW, Wait C, Town A, Heinrich MC (2004) KIT mutations are common in testicular Seminomas. Am J Pathol 164(1):305-313
30. Kim HJ, Lim SJ, Park K, Yuh YJ, Jang SJ, Choi J (2005) Multiple gastrointestinal stromal tumors with a germline c-kit mutation. Pathol Int 55(10):655-659
31. Lemmon MA, Pinchasi D, Zhou M, Lax I, Schlessinger J (1997) Kit receptor dimerization is driven by bivalent binding of stem cell factor. J Biol Chem 272:6311-6317
32. Lev S, Yarden Y, Givol D (1992) Dimerization and activation of the kit receptor by monovalent and bivalent binding of the stem cell factor. J Biol Chem 267:15970-15977
33. Lindahl E, Azuara C, Koehl P, Delarue M (2006) NOMAD-Ref: visualization, deformation and refinement of macromolecular structures based on all-atom normal mode analysis. Nucleic Acids Res 34:52-56
34. López G, Valencia A, Tress ML (2007) Firestar-prediction of functionally important residues using structural templates and alignment reliability. Nucleic Acids Res 35:573-577
35. Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterfield JH, McMahon G, Longley BJ (2002) The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99(5):1741-1744
36. McLean SR, Gana-Weisz M, Hartzoulakis B, Frow R, Whelan J, Selwood D, Boshoff C (2005) Imatinib binding and cKIT inhibition is abrogated by the cKIT kinase domain I missense mutation Val654Ala. Mol Cancer Ther 4(12):2008-2015
37. Mol CD, Dougan DR, Schneider TR, Skene RJ, Kraus ML, Scheibe DN, Snell GP, Zou H, Sang BC, Wilson KP (2004) Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J Biol Chem 279(30):31655-31663
38. Ng PC, Henikoff S (2001) Predicting deleterious amino acid substitutions. Genome Res 11(5):863-874
39. Ng PC, Henikoff S (2003) SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 31(13):3812-3814
40. Nishida T, Kanda T, Nishitani A, Takahashi T, Nakajima K, Ishikawa T, Hirota S (2008) Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor. Cancer Sci 99(4):799-804
41. Parthasarathy S, Murthy MR (2000) Protein thermal stability: insights from atomic displacement parameters (B values). Protein Eng 13:9-13
42. Philo JS, Wen J, Wypych J, Schwartz MG, Mendiaz EA, Langley KE (1996) Human stem cell factor dimer forms a complex with two molecules of the extracellular domain of its receptor, Kit. J Biol Chem 271:6895-6902
43. Rajasekaran R, George Priya Doss C, Sudandiradoss C, Ramanathan K, Purohit R, Sethumadhavan R (2008a) Effect of deleterious nsSNP on the HER2 receptor based on stability and binding affinity with herceptin: a computational approach. C R Biol 331(6):409-417
44. Rajasekaran R, Priya Doss CG, Sudandiradoss C, Ramanathan K, Sethumadhavan R (2008b) In silico analysis of structural and functional consequences in p16INK4A by deleterious nsSNPs associated CDKN2A gene in malignant melanoma. Biochimie 90(10):1523-1529
45. Ramensky V, Bork P, Sunyaev S (2002) Human non-synonymous SNPs: server and survey. Nucleic Acids Res 30(17):3894-3900
46. Ringe D, Petsko GA (1986) Study of protein dynamics by X-ray diffraction. Methods Enzymol 131:389-433
47. Roberts KG, Odell AF, Byrnes EM, Baleato RM, Griffith R, Lyons AB, Ashman LK (2007) Resistance to c-KIT kinase inhibitors conferred by V654A mutation. Mol Cancer Ther 6(3):1159-1166
48. Roskoski R Jr (2005) Structure and regulation of Kit protein-tyrosine kinase-the stem cell factor receptor. Biochem Biophys Res Commun 338(3):1307-1315
49. Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103:211-225
50. Schneidman-Duhovny D, Inbar Y, Nussinov R, Wolfson HJ (2005) PatchDock and SymmDock: servers for rigid and symmetric docking. Nucleic Acids Res 33:363-367
51. Sharma S, Ding F, Nie H, Watson D, Unnithan A, Lopp J, Pozefsky D, Dokholyan NV (2006) iFold: a platform for interactive folding simulations of proteins. Bioinformatics 22(21):2693-2694
52. Suhre K, Sanejouand YH (2004) ElNemo: a normal mode web-server for protein movement analysis and the generation of templates for molecular replacement. Nucleic Acids Res 32:610-614
53. Tan A, Westerman D, McArthur GA, Lynch K, Waring P, Dobrovic A (2006) Sensitive detection of KIT D816V in patients with mastocytosis. Clin Chem 52(12):2250-2257
54. Teng S, Madej T, Panchenko A, Alexov E (2009) Modeling effects of human single nucleotide polymorphisms on protein-protein interactions. Biophys J 96(6):2178-2188
55. Ullrich A, Schlessinger J (1990) Signal transduction by receptors with tyrosine kinase activity. Cell 61:203-212
56. Varfolomeev SD, Uporov IV, Fedorov EV (2002) Bioinformatics and molecular modeling in chemical enzymology. Active sites of hydrolases. Biochemistry (Mosc) 67(10):1099-1108
57. Weisberg E, Griffin JD (2003) Resistance to imatinib (Glivec): update on clinical mechanisms. Drug Resist Updat 6(5):231-238
58. Yip YL, Scheib H, Diemand AV, Gattiker A, Famiglietti LM, Gasteiger E, Bairoch A (2004) The Swiss-Prot variant page and the ModSNP database: a resource for sequence and structure information on human protein variants. Hum Mutat 23(5):464-470
59. Yip YL, Famiglietti M, Gos A, Duek PD, David FP, Gateau A, Bairoch A (2008) Annotating single amino acid polymorphisms in the UniProt/Swiss-Prot knowledgebase. Hum Mutat 29(3): 361-366
60. Yuan Z, Bailey TL, Teasdale RD (2005) Prediction of protein B-factor profiles. Proteins 58(4):905-912
61. Zhang C, Vasmatzis G, Cornette JL, DeLisi C (1997) Determination of atomic desolvation energies from the structures of crystallized proteins. J Mol Biol 267(3):707-726